清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial

托珠单抗 医学 安慰剂 间质性肺病 内科学 不利影响 胃肠病学 随机对照试验 临床终点 外科 病理 疾病 替代医学
作者
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Bridget K. Wagner,Mauro Zucchetto,Ganesh Raghu,Fernando J. Martínez,Jonathan Goldin,Jeffrey Siegel,Christopher P. Denton
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:205 (6): 674-684 被引量:90
标识
DOI:10.1164/rccm.202103-0714oc
摘要

Rationale: Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant effect on skin sclerosis but preserved lung function over 48 weeks in patients with early systemic sclerosis (SSc)-associated interstitial lung disease (ILD) in a phase 3 randomized controlled trial. Objectives: Assess long-term safety and efficacy of tocilizumab. Methods: Adults with diffuse cutaneous SSc for ⩽60 months and elevated acute-phase reactants, including those with ILD, received weekly placebo or tocilizumab 162 mg subcutaneously in the 48-week, double-blind period and then open-label tocilizumab from Weeks 48 to 96 (placebo-tocilizumab; continuous-tocilizumab). Measurements and Main Results: Eighty-two of 107 patients in the placebo-tocilizumab group and 85 of 105 patients in the continuous-tocilizumab group completed 96 weeks. Mean age and disease duration were 48 years and 23 months; high-resolution computed tomography revealed ILD in 61%. Mean (95% confidence interval [CI]) change in modified Rodnan skin score from baseline to week 96 was -8.4 (-10.0 to -6.8) for placebo-tocilizumab and -9.6 (-10.9 to -8.4) for continuous-tocilizumab. Mean (95% CI) change in FVC (percent predicted) from baseline to week 96 was -3.3 (-5.1 to -1.5) for placebo-tocilizumab and -0.5 (-2.4 to 1.3) for continuous-tocilizumab among completers and, in a post hoc analysis, -4.1 (-6.7 to -1.6) and -0.6 (-3.1 to 2.0), respectively, among completers with ILD (mean [95% CI] change from Weeks 48 to 96: 0.9 [-0.8 to 2.7] and -0.4 [-2.3 to 1.5], respectively). Rates per 100 patient-years of serious adverse events from Weeks 48 to 96 were 14.8 for placebo-tocilizumab and 15.8 for continuous-tocilizumab. Conclusions: Tocilizumab preserved lung function, slowing decline in FVC, in patients with SSc, including those with ILD. Long-term safety was consistent with the known safety profile of tocilizumab. Clinical trial registered with www.clinicaltrials.gov (NCT02453256).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Sinner发布了新的文献求助10
6秒前
11秒前
11秒前
13秒前
xhcccc发布了新的文献求助20
14秒前
SciGPT应助跳跃的代曼采纳,获得10
37秒前
Yolo完成签到 ,获得积分10
43秒前
46秒前
跳跃的代曼完成签到,获得积分10
59秒前
1分钟前
xhcccc完成签到,获得积分10
1分钟前
白天亮完成签到,获得积分10
1分钟前
2分钟前
wujiwuhui完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
3分钟前
Jasper应助科研通管家采纳,获得10
3分钟前
爆米花应助bju采纳,获得10
3分钟前
3分钟前
TOUHOUU完成签到 ,获得积分10
3分钟前
4分钟前
4分钟前
领导范儿应助科研通管家采纳,获得10
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
科研通AI5应助科研通管家采纳,获得10
5分钟前
沐浠完成签到 ,获得积分10
5分钟前
葛力完成签到,获得积分20
5分钟前
科研通AI2S应助葛力采纳,获得10
6分钟前
6分钟前
宇文非笑完成签到 ,获得积分0
6分钟前
科研通AI5应助laodai8855采纳,获得20
6分钟前
6分钟前
乾坤侠客LW完成签到,获得积分10
7分钟前
7分钟前
lixuebin完成签到 ,获得积分10
7分钟前
科研通AI2S应助葛力采纳,获得10
7分钟前
lxh完成签到 ,获得积分10
7分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968504
求助须知:如何正确求助?哪些是违规求助? 3513318
关于积分的说明 11167279
捐赠科研通 3248691
什么是DOI,文献DOI怎么找? 1794414
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804652